Shire To Begin Promoting Adderall XR Adult Indication
This article was originally published in The Pink Sheet Daily
Executive Summary
Adults represent 15%-20% of Adderall XR total scripts, Shire says. The company will be required to submit additional clinical data to receive approval for doses above 30 mg.
You may also be interested in...
ADHD Market Hurt By Safety Concerns, Lilly Says
Strattera marketer says that label change and withdrawal of Shire's Adderall XR in Canada has slowed the growth of the attention deficit/hyperactivity disorder market. Lilly will focus on consumers with new DTC ad designed to encourage adult patients to seek treatment.
ADHD Market Hurt By Safety Concerns, Lilly Says
Strattera marketer says that label change and withdrawal of Shire's Adderall XR in Canada has slowed the growth of the attention deficit/hyperactivity disorder market. Lilly will focus on consumers with new DTC ad designed to encourage adult patients to seek treatment.
Health Canada Requests Safety Data Profiles For ADHD Stimulant Drugs
Health Canada requests that manufacturers of stimulants to treat attention deficit/hyperactivity disorder submit "thorough" safety data reviews following the suspension of sales in Canada of Shire's Adderall XR